Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein PSE3 (proteasome activator subunit 3) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring PSE3 in said sample. Measurement of PSE3 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein RLA-0 (60S acidic ribosomal protein P0) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring RLA-0 in said sample. Measurement of RLA-0 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein SPEE (sperrnidine synthase) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring SPEE in said sample. Measurement of SPEE can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein PLST (T-plastin) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring PLST in said sample. Measurement of PLST can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein PRN3/ILEU and/or unbound PRN3 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring PRN3/ILEU and/or unbound PRN3 in said sample. Measurement of PRN3/ILEU and/or unbound PRN3 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention relates to the diagnosis of breast cancer. It discloses the use of protein cellular retinoic acid binding protein II in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring cellular retinoic acid binding protein II in said sample. Measurement of cellular retinoic acid binding protein II can, e.g., be used in the early detection or diagnosis of breast cancer.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein MASP in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring MASP in said sample. Measurement of MASP can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: A separation device and a separation method for biomolecular sample material and in particular protein mixtures. For this purpose a separation element 10 for the two-dimensional and preferable electrophoretic separation of components of the sample material is provided in area 30 of a separation plane. According to the invention it is proposed that the separation element 10 has a channel or transfer structure 14 for the locally resolved discharge of separated sample components in a transport direction that is at right angles to the separation plane onto a support surface 16 that is preferably suitable for mass spectroscopic analyses.

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of the protein nicotinamide N-methyltransferase (NNMT) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring NNMT in said sample. Measurement of NNMT can, e.g., be used in the early detection or diagnosis of colorectal cancer.

Abstract: The present invention relates to novel host cell targets for antiviral, preferably anti-hepatitis C virus (HCV), compounds identified by analysis of HCV replicon-regulated polypeptide expression, to prognostic markers for the prediction of the outcome of a viral infection, to in vitro methods for the prediction of the outcome of a HCV infection in a subject, to screening methods for identifying compounds which interact with and/or modulate the activity of the novel host cell targets or which modulate the expression of said novel host cell targets.

Abstract: A microtiter plate for processing samples, having a liquid component or a liquid and a solid component or a liquid and a gel component, comprising: a single piece body which has an array of cavities, each cavity having an open upper end, a closed bottom end, and a bottom inner surface and comprises a first chamber for receiving a predetermined volume of a sample to be processed, a second chamber and a passage which fluidically connects the first and second chambers with each other, and a region in the lower part of passage adjacent to the bottom end of the cavity, the region so configured and dimensioned that it allows passage of liquid from one of said chambers to the other only when a centrifugal force is applied to the microtiter plate, but does not allow passage of any solid or gel component the size of which is larger than the width of the region.

Abstract: The invention provides a method for the quantification of a biomolecule in a complex mixture of biomolecules which comprises a fractionation of the mixture of biomolecules providing at least two fractions with at least one distinct component each. These fractions are then subjected to serial combinatorial dilution. Subsequently, the biomolecule is detected and identified in the fractions by a method providing a sensitivity threshold and identify information. The quantity of the biomolecule is determined by summarizing the number of identifications of the biomolecule in each fraction on each dilution level in consideration of the respective dilution factor. For purpose of normalization this sum may be divided by the total number of identifications of all biomolecules in all fractions on all dilution levels.